• Let’s Connect at the 2018 NACHC CHI & EXPO!

    In just a couple weeks, RxStrategies’ Rhodie Smith and Justin Rolling will attend the National Association of Community Health Centers’ 2018 Community Health Institute (CHI) & EXPO! Taking place August 24-28, 2018 in Orlando, FL, this gathering is the largest of its kind, offering opportunities for health center clinicians, executives, consumer board members and other… Read more »

  • Clinical Insights: August 3, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Mulpleta® (lusutrombopag) – July 31, 2018 – The Food and Drug Administration approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are… Read more »

  • 340B Insider – July 2018

    Welcome to the July edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.   UPDATES FROM THE 340B COALITION SUMMER CONFERENCE It was great to connect with so many of our clients and industry leaders during the 340B Coalition Summer Conference in Washington D.C. In addition to being a… Read more »

  • Clinical Insights: July 19, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval SymtuzaTM (darunavir, cobicistat, emtricitabine and tenofovir alafenamide) – July 17, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration… Read more »

  • June 2018 – 340B Insider

                    Welcome to the June edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.   340B INDUSTRY NEWS Read below for recent news from 340B Health. HELP Committee Hearing Update: Support for 340B Hospitals and Other Providers Continues Members of… Read more »

  • Clinical Insights: June 21, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Moxidectin – June 13, 2018 – Medicines Development for Global Health (MDGH) and the World Health Organisation Special Programme for Research and Training in Tropical Diseases… Read more »

  • Clinical Insights: June 13, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval FulphilaTM (pegfilgrastim-jmdb) – New Biosimilar Drug Approval – June 4, 2018 – The U.S. Food and Drug Administration approved FulphilaTM (pegfilgrastim-jmdb) as the first biosimilar to Neulasta®(pegfilgrastim) to… Read more »

  • Clinical Insights: June 4, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Olumiant® (baricitinib) – June 1, 2018 – Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has approved the 2-mg… Read more »

  • Discover Program Compliance with RxStrategies

    At RxStrategies, we work with Covered Entities (CE) to create customized 340B solutions that proactively position CEs to maintain compliance implementing internal processes, controls and protocols for internal audits and review purposes. Our 340B CompliancePlus solution also promotes the benefits of engaging broad-based CE teams in program compliance and support and provides them with tools to… Read more »

  • Clinical Insights: May 23, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Doptelet® (avatrombopag) – May 21, 2018 – The Food and Drug Administration approved avatrombopag (Doptelet®, AkaRx Inc.) for thrombocytopenia in adults with chronic liver disease scheduled to… Read more »